Renal Denervation for Uncontrolled Hypertension

Renal denervation (including radiofrequency and ultrasound systems) is covered as an adjunctive treatment to reduce blood pressure in adults with uncontrolled or resistant hypertension—generally those with BP >130/80 mmHg despite three or more antihypertensive agents from different classes at maximally tolerated doses, or patients intolerant of medications, with priority consideration for those at higher cardiovascular risk (e.g., CAD, diabetes, prior TIA/CVA, CKD). Coverage requires shared decision‑making, performance at experienced multidisciplinary hypertension centers, and is subject to member benefit rules; it is contraindicated or not supported by evidence in settings such as pregnancy, fibromuscular dysplasia, renal artery stent/aneurysm/significant stenosis, advanced CKD (stage 4–5), single kidney or transplant recipients, stage 1 or isolated systolic hypertension, and redo procedures.

"Adults with blood pressure >130/80 mmHg despite use of 3 or more antihypertensive medications from at least 3 classes (ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics, beta block..."